Physician profile
William Chamberlain
NPI 1760857247
$1,603.69
in general payments reported to CMS, 2019-2025
23 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $277 · 2022: $308 · 2023: $133 · 2024: $644 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,018.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $328.93 | 2021-2025 | Ozempic, Rybelsus |
| Antares Pharma, INC. | $203.42 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Astrazeneca Pharmaceuticals LP | $145.85 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Exact Sciences Corporation | $104.72 | 2024 | Cologuard Collection Kit |
| Medtronic, INC. | $103.49 | 2024 | Intellis Adaptivestim |
| Bayer Healthcare Pharmaceuticals INC. | $89.46 | 2021-2025 | |
| Nevro Corp. | $83.82 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.61 | 2022-2025 | Jardiance |
| Lilly USA, LLC | $69.53 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Otsuka America Pharmaceutical, INC. | $62.25 | 2022-2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $50.42 | 2023-2025 | Voquezna |
| Pfizer INC. | $37.07 | 2023 | |
| Abbvie INC. | $33.58 | 2024-2025 | |
| Glaxosmithkline, LLC. | $30.86 | 2024 | Arexvy, Trelegy Ellipta |
| Vertex Pharmaceuticals Incorporated | $28.57 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $22.49 | 2022 | |
| Sanofi-Aventis U.S. LLC | $22.00 | 2022 | |
| Saluda Medical Americas, INC. | $21.87 | 2025 | Evoke |
| Mylan Specialty L.P. | $21.80 | 2021 | |
| Redhill Biopharma INC. | $19.91 | 2022 | |
| Daiichi Sankyo INC. | $18.26 | 2024 | Injectafer |
| Verity Pharmaceuticals INC. | $16.45 | 2025 | Tlando |
| Phadia US INC. | $12.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Chamberlain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.